Your browser doesn't support javascript.
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.
Jones, Nick K; Rivett, Lucy; Seaman, Shaun; Samworth, Richard J; Warne, Ben; Workman, Chris; Ferris, Mark; Wright, Jo; Quinnell, Natalie; Shaw, Ashley; Goodfellow, Ian G; Lehner, Paul J; Howes, Rob; Wright, Giles; Matheson, Nicholas J; Weekes, Michael P.
  • Jones NK; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.
  • Rivett L; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom.
  • Seaman S; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.
  • Samworth RJ; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom.
  • Warne B; Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.
  • Workman C; Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United Kingdom.
  • Ferris M; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.
  • Wright J; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom.
  • Quinnell N; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Shaw A; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Goodfellow IG; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Lehner PJ; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Howes R; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.
  • Wright G; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.
  • Matheson NJ; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Weekes MP; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Elife ; 102021 04 08.
Article in English | MEDLINE | ID: covidwho-1173059
ABSTRACT
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK's first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Diagnostic study / Experimental Studies Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: ELife.68808

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Diagnostic study / Experimental Studies Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: ELife.68808